The partners plan to expand testing for early detection of childhood leukemias and lymphomas, bolster local testing capacity, and conduct a research study.

Abbott reported $9.34 billion in diagnostics revenues in 2024, down 7 percent on a reported basis from $9.99 billion in 2023 and down 4 percent on an organic basis. Excluding COVID-19 testing-related ...

The Amsterdam-based biotech firm said that its melt curve analysis-based test is used as a first-tier genetic screening tool to aid the diagnosis of SMA.

Medix said the acquisition adds to its portfolio of raw materials used for in vitro diagnostics development and improves its ability to support immunoassay developers.

The government alleges that BioReference submitted claims to federal healthcare programs for blood tests that were not ordered by a patient's provider.

The government alleges that BioReference submitted claims to federal healthcare programs for blood tests that were not ordered by a patient's provider.

The QuickFinder COVID-19/Flu Antigen Self-Test and the QuickFinder COVID-19/Flu Antigen Pro Test detect SARS-CoV-2, influenza A, and influenza B in swab specimens and provide results within 15 minutes ...

The FDA granted marketing clearances for infectious disease tests, updates to a digital pathology system, and immunoassays for chronic diseases.

NEW YORK – Guardant Health announced Tuesday that its Guardant Reveal liquid biopsy test has received coverage from Medicare administrative contractor Palmetto GBA to monitor colorectal cancer ...

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

The FoundationOne test can be used to identify patients with relapsed or refractory BRAF-altered pediatric low-grade glioma who may be eligible for therapeutic options.

NEW YORK — Owlstone Medical, a UK-based developer of breath-based diagnostics, said Wednesday that it has closed a $27 million Series E financing round.